Milestone Pharmaceuticals is trading 15.75% down at $1.07 ahead of its scheduled second-quarter 2026 financial-results release before the market open on August 12, 2026.
- Investor conference call scheduled for 8:30 a.m. ET.
- Analysts expected a quarterly loss of approximately $0.18 per share and revenue near $0.817 million, focusing investors on Cardamist commercial traction, cash usage, and forward guidance.
- Broader indexes are modestly higher pre-market, so the decline appears primarily company-specific rather than market-driven.